Opus Genetics Beheer

Beheer criteriumcontroles 2/4

De CEO Opus Genetics is George Magrath, benoemd in Nov2023, heeft een ambtstermijn van 2.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 889.24K, bestaande uit 64.7% salaris en 35.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.1% van de aandelen van het bedrijf, ter waarde $ 1.54M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 5.1 jaar.

Belangrijke informatie

George Magrath

Algemeen directeur

US$889.2k

Totale compensatie

Percentage CEO-salaris	64.66%
Dienstverband CEO	2.1yrs
Eigendom CEO	1.1%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Dec 11

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Sep 09

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Jul 11

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

May 19

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Apr 09

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Aug 19

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Jul 24

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Jul 12

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

May 02

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Mar 15

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

May 20

Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%

Apr 02

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Jan 27

Analyse CEO-vergoeding

Hoe is George Magrath's beloning veranderd ten opzichte van Opus Genetics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2025	n/a	n/a	-US$68m
Jun 30 2025	n/a	n/a	-US$58m
Mar 31 2025	n/a	n/a	-US$59m
Dec 31 2024	US$889k	US$575k	-US$58m
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$96k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 889.24K ) George } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 577.34K ).

Compensatie versus inkomsten: De vergoeding van George is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

George Magrath (41 yo)

2.1yrs

Tenure

US$889,238

Compensatie

Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment Research Limited si...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
George Magrath	CEO & Director	2.1yrs	US$889.24k	1.1% $ 1.5m
Benjamin Yerxa	President & Director	1.2yrs	geen gegevens	0.10% $ 140.2k
Ashwath Jayagopal	Chief Scientific & Development Officer	1.8yrs	US$1.24m	0.025% $ 34.5k
Robert Gagnon	CFO & Principal Accounting Officer	less than a year	geen gegevens	geen gegevens
Joseph Schachle	Chief Operating Officer	2.1yrs	geen gegevens	0.0029% $ 4.0k
Jenny Kobin	Investor Relations Officer	no data	geen gegevens	geen gegevens
Bernhard Hoffmann	Senior Vice President of Corporate Development & Secretary	no data	US$789.92k	0.17% $ 237.6k
Bindu Manne	Head of Market Development & Commercialization	3.9yrs	geen gegevens	geen gegevens
Sally Tucker	Senior Vice President of Clinical Development	no data	geen gegevens	geen gegevens
Erik Sims	Director & Corporate Controller	no data	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IRD wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
George Magrath	CEO & Director	2.1yrs	US$889.24k	1.1% $ 1.5m
Benjamin Yerxa	President & Director	no data	geen gegevens	0.10% $ 140.2k
James S. Manuso	Independent Director	5.1yrs	US$184.43k	0.20% $ 285.1k
Adrienne Graves	Independent Director	1.2yrs	US$192.82k	geen gegevens
David Boyer	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Richard Rodgers	Independent Director	5.1yrs	US$267.48k	0.35% $ 483.1k
Susan Benton	Independent Director	5.1yrs	US$176.39k	0.20% $ 282.9k
Cameron Gallagher	Independent Chairman	5.1yrs	US$219.61k	2.51% $ 3.5m
Sean Ainsworth	Lead Independent Director	5.1yrs	US$200.22k	0.25% $ 354.1k
Jean Bennett	Director	1.2yrs	US$325.82k	0.049% $ 68.7k
Arshad Khanani	Member of Medical Advisory Board	1.8yrs	geen gegevens	geen gegevens
Mark Pennesi	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IRD wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/12/28 22:59
Aandelenkoers aan het einde van de dag	2025/12/26 00:00
Inkomsten	2025/09/30
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Opus Genetics, Inc. wordt gevolgd door 9 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
James Molloy	Alliance Global Partners
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets

Opus Genetics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

CEO & Director recently bought US$98k worth of stock

CEO & Director recently bought US$101k worth of stock

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Recent updates

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Consensus EPS estimates fall by 16%, revenue upgraded

Third quarter 2025 earnings: EPS misses analyst expectations

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $23 million.

Price target increased by 13% to US$6.80

New major risk - Revenue and earnings growth

Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in September

Opus Genetics, Inc. announced that it has received $3.5 million in funding

Consensus revenue estimates decrease by 18%, EPS upgraded

Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate OPGx-Best1

New major risk - Financial position

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Consensus revenue estimates increase by 16%

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Price target decreased by 13% to US$9.25

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Consensus revenue estimates increase by 34%

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

New major risk - Shareholder dilution

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

CEO & Director recently bought US$98k worth of stock

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 21% to US$13.67

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Consensus revenue estimates increase by 62%

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 12% to US$17.25

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Full year 2023 earnings: EPS and revenues miss analyst expectations

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 17%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors